Tag: IHL
Incannex Healthcare completes dosing in phase two proof-of-concept trial of IHL-42X for obstructive sleep apnoea
Cannabinoid and psychedelics biotech Incannex Healthcare (ASX: IHL) has completed dosing of participants in its phase two proof-of-concept clinical trial of IHL-42X for the treatment of obstructive sl...
Incannex Healthcare to pursue US public offering and Nasdaq listing next month
Incannex Healthcare (ASX: IHL) has announced it is targeting a public offering and Nasdaq listing of American Depositary Shares in the United States next month.
The company revealed today it has ad...
Incannex Healthcare receives pre-IND guidance and ethics approval to begin phase 2a psychedelic trial
Psychedelic and cannabinoid biotech company Incannex Healthcare (ASX: IHL) has received ethics approval to proceed with a phase 2a psilocybin-assisted psychotherapy clinical trial for patients with cr...
Incannex Healthcare moves forward with soft gel capsule design for IHL-42X to treat obstructive sleep apnoea
Cannabinoid and psychedelic biotech company Incannex Healthcare (ASX: IHL) has engaged pharmaceuticals manufacturer Procaps SA to develop a soft gel capsule form of its IHL-42X cannabinoid drug for th...
Incannex Healthcare raises close to $18m, including $8m from chief medical officer
Clinical-stage cannabinoid and psychedelics medicine developer Incannex Healthcare (ASX: IHL) has announced it has raised almost $18 million via the completion of option exercises.
A total of 118 m...
Incannex Healthcare proposes US IPO and Nasdaq listing
Clinical-stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has filed a registration statement with the United States Securities and Exchange Commission (SEC) relating to a propos...
Incannex Healthcare submits proposals for phase two psychedelics study to treat generalised anxiety disorder
Clinical-stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has completed a Human Research Ethics Committee submission for a phase 2a Psi-GAD study, which combines the administrat...
Incannex Healthcare begins clinical trial using IHL-675A soft gel capsules
Clinical stage cannabinoid and psychedelic medicine development company Incannex Healthcare (ASX: IHL) has started a phase 1 clinical trial assessing a soft gel capsule formulation of its multi-use dr...
Incannex files patent application for IHL-42X and receives ethics approval for open label extension
Clinical stage cannabinoid and psychedelic development company Incannex Healthcare (ASX: IHL) has filed an international patent application as part of the development program for its drug IHL-42X for ...
Incannex Healthcare appoints Procaps to develop capsule formulations for drug IHL-675A
Specialised pharmaceutical manufacturer Procaps SA has been engaged by Incannex Healthcare (ASX: IHL) to develop the specific formulation for its drug IHL-675A using Procaps’ Unigel capsule technology...
Incannex Healthcare to develop IHL-216A formulation for traumatic brain injury clinical trials
Cannabinoid development company Incannex Healthcare (ASX: IHL) has announced it has engaged drug manufacturer Vectura Limited to develop the specific formulation required for clinical trials of IHL-21...
Incannex partners with University of WA as additional site for ongoing phase 2b sleep apnoea trial
Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has engaged the University of Western Australia’s Centre for Sleep Science as an additional site for an ongoing trial i...
First subsidised CBD oil shows promise for Incannex Healthcare’s own medical cannabis drugs in Australia
In a historic first, a medicinal cannabis drug has been listed on Australia’s Pharmaceutical Benefits Scheme (PBS), enabling Australians living with Dravet syndrome access to treatment for the rare fo...
Incannex Healthcare plans US regulatory pathway for IHL-675A in treating multiple inflammatory conditions
Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has held a pre-investigational new drug application meeting with the US Food and Drug Administration (US FDA) to discus...
With their mind-blowing medical potential, are hallucinogens the next ASX ‘pot stock’ equivalent?
The mere mention of magic mushrooms, ecstasy or ketamine is enough to send parents of teenagers into conniptions. But are these so-called party drugs poised to follow cannabis into the realm of a medi...
Incannex Healthcare secures pre-IND meeting with US FDA to progress IHL-675A in treating SAARDS and ARDS
Incannex Healthcare (ASX: IHL) will confer with the United States Food and Drug Administration after the body granted a pre-investigational new drug meeting regarding progressing the company’s IHL-675...
Incannex Healthcare study results point to IHL-675A as a treatment option for rheumatoid arthritis
Positive results from an in vivo study model using Incannex Healthcare’s (ASX: IHL) lead candidate IHL-675A have triggered the launch of a sixth clinical program investigating the benefits of the drug...
Incannex Healthcare and Monash Trauma Group to undertake sports concussion study using model developed by the NFL
Incannex Healthcare (ASX: IHL) has revealed it will work with Monash Trauma Group on an “extensive” in vivo study evaluating the protective effect of IHL-216A in sports concussion.
Monash Trauma Gr...
Incannex Healthcare’s drug candidate IHL-675A could become a multi-use medication
Incannex Healthcare (ASX: IHL) has been buoyed by the potential of its candidate IHL-675A to become a multi-use medication after receiving positive results from another pre-clinical in vivo trial into...
Incannex Healthcare attracts interest as Austrian clinic uses CBD to treat COVID-19
News that an Austrian hospital using medical cannabis to treat patients with COVID-19 has yielded positive results is spurring investor interest in Incannex Healthcare (ASX: IHL), according to the Aus...
Incannex Healthcare study finds lead drug IHL-675A has ‘superior’ anti-inflammatory capabilities
Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has received positive results from an additional in vivo study in assessing the anti-inflammatory capabilities of its l...
